<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002882</url>
  </required_header>
  <id_info>
    <org_study_id>ID95-196</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-95196</secondary_id>
    <secondary_id>MDA-DM-95196</secondary_id>
    <secondary_id>NCI-G96-1089</secondary_id>
    <secondary_id>CDR0000065188</secondary_id>
    <nct_id>NCT00002882</nct_id>
  </id_info>
  <brief_title>Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma</brief_title>
  <official_title>Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may
      stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether
      interferon alfa plus combination chemotherapy and interleukin-2 is more effective than
      interferon alfa alone in treating patients with melanoma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or
      without combination chemotherapy plus interleukin-2 in treating patients with melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of postoperative adjuvant therapy with interferon alfa-2b (IFN-A)
           administered subcutaneously with or without IV induction vs concurrent biochemotherapy
           including cisplatin, vinblastine, DTIC, IFN-A and IL-2 and in melanoma patients with
           regional lymph node metastases that have been surgically resected.

        -  Determine the relative toxic effects associated with adjuvant therapy with IFN-A and
           concurrent biochemotherapy including cisplatin, vinblastine, DTIC, IFN-A, and IL-2 and
           their effect on the quality of life.

        -  Determine the prognostic value of detection of melanoma cells in the peripheral blood
           using RT/PCR for tyrosinase mRNA.

      OUTLINE: This is a randomized study. All patients are stratified according to prognostic
      factors.

      Patients are randomly allocated to 1 of 2 treatment options. Treatment 1 uses interferon
      alfa-2b (IFN-A) therapy, and treatment 2 includes adjuvant biochemotherapy.

      Patients who are randomized to IFN-A will be further stratified and randomized to one of two
      interferon schedules.

        -  Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A
           maintenance 3 times a week for 48 weeks.

        -  Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks. Adjuvant biochemotherapy
           begins immediately after registration on the study. Cisplatin is given IV on days 1-4;
           vinblastine is given IVPB on days 1-4; dacarbazine (DTIC) is given IVPB on day 1; IFN-A
           is given subcutaneously on days 1-5; IL-2 is given by continuous infusion for a total of
           96 hours on days 1-4. Each course of therapy is repeated every 21 days for 4 courses.
           Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8
           weeks from lymphadenectomy and a week after completion of and recovery from
           radiotherapy.

      PROJECTED ACCRUAL: A total of 200 patients (100 patients in each arm) will be entered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1995</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Interferon Alfa with/without Combination Chemotherapy + Interleukin-2 for Melanoma</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Melanoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>IFN-A Therapy Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-A Therapy Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin (IL-2)</intervention_name>
    <description>Infusion for a total of 96 hours on days 1-4</description>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Interleukin-2</other_name>
    <other_name>Proleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Alfa (IFN-A)</intervention_name>
    <description>IFN-A Therapy Groups:
Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks
Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5</description>
    <arm_group_label>IFN-A Therapy Schedule A</arm_group_label>
    <arm_group_label>IFN-A Therapy Schedule B</arm_group_label>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <other_name>interferon alfa-2b</other_name>
    <other_name>IFN-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV Days 1-4</description>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <other_name>CDDP</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>IVPB on day 1</description>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>IVPB on days 1-4</description>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
    <other_name>Velban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adjuvant Therapy</intervention_name>
    <description>Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.</description>
    <arm_group_label>Adjuvant Biochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically diagnosed malignant melanoma with regional lymph node metastases

          -  Undergone complete lymph node dissection and free of any residual tumor

          -  No greater than 90 days from diagnosis of regional lymph nodes metastases

          -  No distant or resected in-transit metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  10 to 66

          -  66 to 70 if in excellent physical condition

        Performance status:

          -  0-2

        Life expectancy:

          -  At least 12 months

        Hematopoietic:

          -  Hemoglobin greater than 10 g/dL

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.2 mg/dL

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Other:

          -  No serious intercurrent illness that would compromise tolerance of therapy and long
             term survival

          -  Must be able to participate in follow up for minimum of 5 years

          -  No second malignancy except:

               -  In situ cervical cancer

               -  Basal or squamous skin cancer

          -  Must be able to physically and emotionally tolerate biochemotherapy

          -  No history of pulmonary or cardiac dysfunction, e.g., cardiac rhythm disturbance,
             congestive heart failure, coronary bypass, or impaired cardiac ejection fraction

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy with interferon or IL-2

          -  No concurrent immunomodulators

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No concurrent steroids

        Radiotherapy:

          -  Prior adjuvant local radiotherapy allowed for head and neck

        Surgery:

          -  No greater than 8 weeks after definitive surgery for lymph node metastases

        Other:

          -  No concurrent nonsteroid anti-inflammatory drugs, or other prostaglandin synthetase
             inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agop Y. Bedikian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <results_reference>
    <citation>Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.</citation>
    <PMID>19430405</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

